BBIO

H.C. Wainwright reiterates Buy on BridgeBio stock on trial data

What Does BridgeBio Pharma (BBIO) Gain From Its New US Drug Access Deal?

BridgeBio (BBIO) Stock Looks Fully Priced Despite Fresh Acoramidis Data

Mizuho raises BridgeBio Pharma stock price target to $110 on Attruby

BridgeBio Q2 Sales Jump 120% as Attruby Drives Commercial Momentum

BridgeBio Pharma (BBIO) Secured Two Priority Reviews For Rare Disease Drugs

BridgeBio Stock Has Soared 29% in Just 3 Months. Here's Why Wall Street Thinks It Could Go Even Higher.

KKR reportedly assigned almost 60% of BridgeBio stock sale to five firms

KKR to sell 5M BridgeBio shares in secondary offering

BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder

BridgeBio Earnings: Strong Attruby Uptake as Late-Stage Candidates Are Under Regulatory Review

BridgeBio: Attruby Delivers In Q2, Expect Three New Launches In 12 Months (NASDAQ:BBIO)

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma (BBIO) Reports Q2 Loss, Tops Revenue Estimates